Opendata, web and dolomites

GAIT

From symptom relief to disease modifying allergy treatment with Glycan-Allergen Immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GAIT project word cloud

Explore the words cloud of the GAIT project. It provides you a very rough idea of what is the project "GAIT" about.

dose    clinical    ait    therapy    protein    allergens    profitability    symptom    plan    worldwide    decongestants    strategy    allergy    disease    generation    cured    patient    ipr    individuals    suited    global    protection    business    immune    dc4u    license    life    substances    pollen    prevalence    extract    gp    therapeutics    doses    treat    severe    alleviating    modifying    antihistamines    diseases    immunotherapy    medical    safe    market    initialize    negotiations    underlying    self    annual    recognition    healthy    risks    relieving    glycans    investors    plans    incorporated    elaborate    20    sia    efficacy    alarming    allergen    endogenous    mechanisms    medicine    chronic    inducing    company    tolerance    develops    instead    grass    followed    course    elaborated    placebo    iia    curative    responsible    licensing    characterised    pharmaceutical    harm    proprietary    replace    treatment    corticosteroids    shown    healthcare    attempts    sme    human    vivo    trials    pace    refine    dominated   

Project "GAIT" data sheet

The following table provides information about the project.

Coordinator
DC4U 

Organization address
address: DE CORRIDOR 21E
city: BREUKELEN
postcode: 3621 ZA
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.dc4u-technologies.nl
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DC4U NL (BREUKELEN) coordinator 50˙000.00

Map

 Project objective

The annual increase in prevalence of allergy related diseases develops at an alarming pace worldwide. Responsible disease mechanisms are characterised by unwanted immune responses to substances which do not harm healthy individuals. The allergy therapeutics market is now dominated by symptom alleviating antihistamines, decongestants and corticosteroids. The main patient need is to get cured with a disease modifying medicine instead of the chronic use of symptom relieving products. Allergen-specific Immunotherapy (AIT) attempts to treat the underlying cause by inducing allergen-specific immune tolerance. However, currently used AIT with high doses of extract is not effective enough (only 20% better than placebo), risks severe side effects and requires 5 years of treatment.

DC4U is developing a new generation of disease modifying allergy treatment with the potential to replace symptom relieving products and current AIT. We apply a new and unique technology to present allergens to the immune system as being SELF and SAFE, using glycans as endogenous human protein recognition elements. Our lead product, “sia-GP”, is a grass pollen allergy treatment for life long protection, achieved in a short treatment course. DC4U has shown highly promising in-vivo dose-response efficacy results and will further develop this proprietary product up to and including Phase IIa clinical trials. This will be followed by out-licensing to a pharmaceutical company. Effective curative tolerance inducing therapy will contribute to global medical needs and reduction of healthcare costs.

In this SME-1 we will elaborate and refine our clinical plans, IPR strategy, market analysis and profitability analysis. Furthermore, we will initialize discussions and negotiations with several possible investors and licensing partners. All will be incorporated in an elaborated European business plan with best suited to out-license sia-GP after Phase IIa clinical trials.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GAIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GAIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More  

SINUSLIGHT (2018)

Laser-spectroscopic sensing device for diagnostic assessment of sinusitis

Read More